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Despite manifold efforts to achieve reduced-intensity and -toxicity regimens, secondary
leukemia has remained the most severe side effect of chemotherapeutic cancer
treatment. Rearrangements involving a short telomeric <1 kb region of the mixed lineage
leukemia (MLL) gene are the most frequently observed molecular changes in secondary
as well as infant acute leukemia. Due to the mode-of-action of epipodophyllotoxins
and anthracyclines, which have widely been used in cancer therapy, and support from
in vitro experiments, cleavage of this MLL breakpoint cluster hotspot by poisoned
topoisomerase II was proposed to trigger the molecular events leading to malignant
transformation. Later on, clinical patient data and cell-based studies addressing a wider
spectrum of stimuli identified cellular stress signaling pathways, which create secondary
DNA structures, provide chromatin accessibility, and activate nucleases other than
topoisomerase II at theMLL. TheMLL destabilizing signaling pathways under discussion,
namely early apoptotic DNA fragmentation, transcription stalling, and replication stalling,
may all act in concert upon infection-, transplantation-, or therapy-induced cell cycle
entry of hematopoietic stem and progenitor cells (HSPCs), to permit misguided cleavage
and error-prone DNA repair in the cell-of-leukemia-origin.
Keywords:MLL breakpoint cluster region, infant acute leukemia, therapy-related leukemia, apoptosis, replication
stress, error-prone DNA repair
Introduction
The KMT2A gene, better known as MLL (mixed lineage or myeloid/lymphoid leukemia) encodes
a lysine (K)-specific histone methyltransferase 2A, which functions as an epigenetic regulator
of transcription (Daniel and Nussenzweig, 2012; Takeda et al., 2013). The enzyme is primarily
connected to hematopoietic and embryonic development (Hess et al., 1997), but was also
described to contribute to the S-phase DNA damage checkpoint (Liu et al., 2010). The gene
spans the breakpoint cluster region at chromosomal position 11q23, frequently rearranged in
acute leukemia, especially in therapy-related and infant cases (Ziemin-van der Poel et al., 1991;
Emerenciano et al., 2007; Cowell and Austin, 2012). Despite over two decades of efforts, the
reasons underlying the exceptionally high breakability of the KMT2A/MLL locus are still not
clear. The same is true also for the mechanisms leading to its rearrangements. In this review
we summarize the facts and hypotheses which in our view are relevant for understanding
of KMT2A/MLL breakage and rearrangements, with a focus on therapy-related cases.
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Incidence and Risk of MLL
Rearrangements
Rearrangements of the MLL gene were found in 5.2% of all
the acute myeloid leukemia (AML) cases and in 22% of all the
acute lymphoid leukemia (ALL) cases (De Braekeleer et al., 2005).
Patients with MLL rearrangements have poorer prognosis than
the ones without, with shorter event free and overall survival
rates (Tamai et al., 2008; Cerveira et al., 2012; Chen et al., 2013).
Interestingly, myelodsyplastic syndrome (MDS) patients with the
11q23 rearrangement t(2; 11)(p21; q23) which does not affect the
MLL gene but rather upregulates a downstream lying miRNA
MIR125B1 resulting in inhibited primary human CD34+ cell
differentiation, have a favorable prognosis (Bousquet et al., 2008;
Dvorak et al., 2014).
In childhood ALL,MLL rearrangements are found in 44–85%
of the infants (<1 year old), which decreases down to 3% in
the elder (1–10 years) patients (Emerenciano et al., 2007, 2013;
Al-Sudairy et al., 2014). Data from siblings revealed that both
genetic and environmental risk factors are implied in childhood
ALL (Schmiegelow et al., 2012). As MLL rearrangements in
these patients can arise during in utero fetal hematopoiesis
(Gale et al., 1997), prenatal exposure and consequently lifestyle
of the mother are highly relevant for development of this
type of leukemia. Increased MLL rearrangements were indeed
observed in amniocytes from long-term smokers in a small
prospective study (de la Chica et al., 2011), as well as a
statistically significant association between intake of hormones
during pregnancy and risk of in utero MLL rearrangements in
a study enrolling several 100 children (Pombo-de-Oliveira et al.,
2006). Estrogen, in particular, was demonstrated to induce MLL
breakage and rearrangements in cultured lymphoblastoid cells
(Schnyder et al., 2009). The most prominent hints to exogenous
MLL destabilizing sources stem from reports on the intake
of dietary flavonoids during pregnancy. Bioflavonoids, such as
quercetin, hydroquinone or genistein which are present in citrus,
certain types of berries and root vegetables, can induce MLL
cleavage and rearrangements ex vivo in human hematopoietic
stem and progenitor cells (HSPCs) isolated from umbilical cord
blood (Strick et al., 2000; van Waalwijk van Doorn-Khosrovani
et al., 2007) and in utero in mice (Vanhees et al., 2011).
With rearrangements found in∼40% of therapy-related acute
leukemia/myelodsyplastic syndrome (t-AL/MDS), MLL is the
most frequently rearranged gene in t-AL (Shivakumar et al.,
2008; Pullarkat et al., 2009; Shim et al., 2010; Abdulwahab et al.,
2012; Cowell and Austin, 2012). The lifelong risk of t-AL/MDS
in patients receiving chemo- and/or radio-therapy was found
to be 0.2% among US cancer patients (Morton et al., 2013).
Depending on the type of primary cancer and especially the
therapy used, it varied between 0.02 and 12% (Maddams et al.,
2011; Abdulwahab et al., 2012; Ezoe, 2012; Koontz et al., 2013;
Morton et al., 2013). The majority of cases occur during the
first 5 years after treatment of primary cancer (Shivakumar
et al., 2008; Pullarkat et al., 2009; Ezoe, 2012; Koontz et al.,
2013). Though causalities are often difficult to assess as patients
receive complex treatments, the highest (up to 12%) incidence
of t-AL was observed in patients treated with topoisomerase
II inhibitors such as epipodophyllotoxins and anthracyclines
(Abdulwahab et al., 2012; Ezoe, 2012). Use of topoisomerase II
inhibitors also seemed connected to over 90% of all the 11q23
rearrangements in patients receiving chemotherapy (Shivakumar
et al., 2008). A causal link between topoisomerase II inhibitor
treatment and MLL rearrangements was supported by in vitro
data on stable MLL rearrangements in human embryonic and
hematopoietic stem cells (HSCs) treated with topoisomerase II
inhibitor etoposide (Libura et al., 2008; Bueno et al., 2009).
Interestingly, bioflavonoids were connected to MLL
rearrangements in infant ALL and were shown to inhibit
human topoisomerase II (Strick et al., 2000), so that causes
for infant ALL might be similar to the ones for t-AL. Both
types of leukemia are characterized by short latency after the
initiation event- exposure of the hematopoietic system to the
MLL destabilizing agents in utero or during primary cancer
treatment, respectively. To the best of our knowledge no links
between bioflavonoids/topoisomerase II-inhibiting compounds
and MLL rearrangements in de novo AL were described so
far. Striking similarities between infant and therapy-related AL
were, however, found when comparing the breakage distribution
within theMLL as discussed below.
Distribution of Break Sites Leading to
Leukemic Rearrangements
More than 95% of the MLL rearrangements fall within a
∼7.3 kb breakpoint cluster region (MLLbcr). This was originally
described to range from exon 9 to intron 11/exon 12 of theMLL
gene (Reichel et al., 2001; Meyer et al., 2013). However, according
to the current reference sequence (GRCh38.p2, http://www.ncbi.
nlm.nih.gov/projects/genome/assembly/grc/human/) this region
corresponds to exon 8—intron 10/exon 11 (Figures 1A,B). For
the purpose of clarity and comparability to publications cited
in this review, we use the original numbering throughout this
paper. Within the MLLbcr the distribution of breaks is not
uniform, but rather forms two clusters which together harbor
∼80% of all the breaks (Meyer et al., 2013). The centromeric
cluster can be attributed mostly to cases of de novo AL in adults,
while breaks from t-AL and infant ALL cluster at the telomeric
part of the MLLbcr (Broeker et al., 1996; Cimino et al., 1997;
Reichel et al., 2001; Cowell and Austin, 2012; Meyer et al., 2013),
in particular, within a short ∼600 bp translocation hotspot at
the intron 11/exon 12 boundary (Mirault et al., 2006). Similar
clustering to intron 11/exon 12 boundary can be found also when
looking at breaks and rearrangements following topoisomerase
II inhibitor and flavonoid treatments (van Waalwijk van Doorn-
Khosrovani et al., 2007; Le et al., 2009), providing further support
for a mechanistic connection between secondary and infant ALL.
Over 100 different rearrangements and over 60 translocation
partners of MLL have been described so far, however most
of them were reported only sporadically (Meyer et al., 2006,
2009). A handful of translocation partners, namely AFF1/AF4,
MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, and MLLT4/AF6,
were found to be involved in 70–95% of theMLL translocations,
with some differences in frequencies of individual partners in
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FIGURE 1 | Position, structure, and regulatory features of MLL
breakpoint cluster region. (A–C) Selected features of the KMT2A/MLL
gene based on current issue of Ensembl data (release 79, March 2015;
http://www.ensembl.org/index.html; Cunningham et al., 2015). (A)
KMT2A/MLL position on chromosome 11, exon structure according to the
(Continued)
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FIGURE 1 | Continued
current reference sequence (Human RefSeq), transcripts (protein coding
and non-protein coding), regulatory features and open chromatin (DNase I
sensitive) sites. Some transcripts harbor exons that are not acknowledged
by the reference sequence (for example compare Human RefSeq,
KMT2A-001 and KMT2A-002). Open chromatin sites are detectable in
promoter-exon 1, exon 12 and exon 37. The position of the breakpoint
cluster region (MLLbcr) is marked by dashed lines. (B) Enhanced view of
the MLLbcr with exon structure of the reference sequence and transcripts,
regulatory features and open chromatin (DNase I) sites. The position of the
therapy-related hotspot is marked by dashed lines. (C) Enhanced view of a
therapy-related hotspot flanking a major therapy-related translocation
breakpoint described by Mirault et al. (2006), with exon structure,
sequence, regulatory features and open chromatin (DNase I) sites. The
major therapy-related breakpoint cluster (marked by red triangle) lies at the
5′ end of intron 11, just 3′ of the DNase I and CTCF-binding site found in
17/18 and 18/18 cell lines used in Ensembl, respectively. The indicated
399bp segment was used in reporter studies with exogenous MLLbcr
fragment (Boehden et al., 2004; Gole et al., 2014; Ireno et al., 2014).
(D) Secondary structure of the 399bp therapy-related hotspot. The
structure was calculated using programs performing searches based on
sequence, namely Quadruplex forming G-Rich Sequences (QGRS) Mapper
(http://bioinformatics.ramapo.edu/QGRS/index.php) and M-Fold for hairpins
(http://mfold.rna.albany.edu/?q=mfold).
ALL vs. AML, infant vs. adult, and de novo vs. therapy-induced
leukemia (Meyer et al., 2009, 2013; De Braekeleer et al., 2011;
Cerveira et al., 2012; Emerenciano et al., 2013). Relatively narrow
assortment of recurrent translocation partnersmost likely reflects
some growth advantage of the mutant cells due to the particular
rearrangement (Strick et al., 2006; Bueno et al., 2009). In line
with this concept, examination of the blood samples from breast
cancer and lymphoma patients undergoing topoisomerase II
inhibitor treatment showed that MLL translocations are much
more common than the actual t-AL cases (Le et al., 2009). Stable
MLL rearrangements in human HSCs treated with etoposide did
indeed increase the proliferative capacity of the cells (Libura et al.,
2008; Bueno et al., 2009), though additional abnormalities seem
to be needed for the completion of malignant transformation
(Bueno et al., 2009). As a prominent example, the MLL-AF9
fusion gene was shown to be actively transcribed (Betti et al.,
2003) and the resulting fusion protein promoted expression
of Hoxa9 transcription factor which has been associated with
leukemic transformation (Muntean et al., 2010). Despite the fact
that reciprocal gene fusions represent the majority of stableMLL
rearrangements, a plethora of additionalMLL aberrations namely
gene-internal duplications, inversions, deletions, insertions,
and complex rearrangements were identified in leukemia
patients (Meyer et al., 2013), underscoring the fact that
the MLLbcr bears intrinsic features causing exceptionally
high fragility.
Which Enzymes Cause MLL Breakage?
Already in the 1990s, MLLbcr breakage and rearrangements
causing secondary leukemia in patients undergoing
chemotherapy were linked to the action of topoisomerase II
inhibitors. Thus, cleavage by topoisomerase II at consensus
sequences within a centromeric MLLbcr fragment was
demonstrated in vitro (Felix et al., 1995). Translocation
breakpoint junctions of a t(4; 11) and a t(9; 11) secondary leukemia
patients were found to coincide with topoisomerase II sensitive
sites, even though not consensus sequences, in the centromeric
and telomericMLLbcr fragment, respectively (Lovett et al., 2001;
Whitmarsh et al., 2003). Characterization of topoisomerase
II inhibitor-induced effects on the MLLbcr in lymphoblasts
from a patient undergoing chemotherapy, in ex vivo treated
peripheral blood cells from healthy individuals and in vitro
treated leukemia cell lines, identified breakage within a telomeric
MLLbcr fragment comprising a topoisomerase II recognition
sequence (Aplan et al., 1996). Topoisomerase II inhibition
by either etoposide or teniposide treatment was shown to
induce the same cleavage pattern in the telomeric MLLbcr
region in lymphoblastoid cells, T47D breast cancer cells, and
human fibroblasts (Mirault et al., 2006). Causal involvement of
topoisomerase II was supported by use of cells with mutated
topoisomerase II showing diminished breakage (Mirault et al.,
2006; Cowell et al., 2012) and by protein expression inducing
hypersensitivity to etoposide (Tamaichi et al., 2013).
Despite these well-supported links between topoisomerase II
action and MLLbcr breakage, several lines of evidence indicate
that topoisomerase II is not essential for this process. First,
using various human leukemia and other cancer cell lines as
well as mouse embryonic fibroblasts, several groups showed
that MLLbcr cleavage depends on apoptosis (but not necrosis)
rather than topoisomerase II, even when cells are treated with
topoisomerase II inhibitors (Stanulla et al., 1997; Betti et al., 2005;
Hars et al., 2006). It was hypothesized that some cells can escape
the cell death process and therefore transform apoptosis-induced
DNA damage into leukemic translocations (Vaughan et al., 2002).
In line with this, it is possible to induce MLLbcr breakage and
rearrangements in cultured cells with a wide range of compounds
not targeting topoisomerase II, such as with topoisomerase I
inhibitor camptothecin, DNA polymerase inhibitor aphidicolin,
microtubule inhibitor vinblastine, antimetabolites (5-
fluorouracil, cytosine arabinoside, methotrexate), alkylating
agents (melphalan, methylmethanesulfonate), the cross-linking
agent cisplatin, with ionizing irradiation, and with various
other genotoxic compounds with less defined modes of action
(Stanulla et al., 1997; Ploski and Aplan, 2001; Sim and Liu,
2001; Betti et al., 2005; Le et al., 2009; Gole et al., 2014; Ireno
et al., 2014; Kraft et al., 2015). It has even been reported that
MLLbcr breakage and rearrangements can be induced by some
non-genotoxic agents such as N-methylformamide (Ploski
and Aplan, 2001) or by estrogen (Le et al., 2009), though for
most non-genotoxic compounds this seems not to be the case
(Ireno et al., 2014). Clinical data also describe 11q23/MLL
rearrangements in patients treated with chemotherapies not
addressing topoisomerase II (Faller et al., 2009; Zámecˇníkova,
2011). Most importantly, catalytic topoisomerase II inhibition
by merbarone prior to formation of the cleavable complex or
RNA interference-mediated silencing of the enzyme did not
abrogate MLLbcr cleavage downstream of different genotoxic
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treatments (Betti et al., 2005). In this context it is important to
note that topoisomerase II poisoning by epipodophyllotoxins
like etoposide relies on the formation of a complex composed of
the drug, DNA, and topoisomerase II blocking DNA re-ligation
and resulting in breakage, i.e., genotoxic stress (Felix et al., 1995).
From these observations it was proposed that signaling events
downstream of topoisomerase II-induced DNA double-strand
break (DSB) formation are the cause of MLLbcr breakage
and/or that several distinct enzymes can be involved (Stanulla
et al., 1997; Mirault et al., 2006). The most widely discussed
signaling mechanism, which underlies MLLbcr breakage is
apoptosis leading to apoptotic DNA fragmentation (Stanulla
et al., 1997; Betti et al., 2001; Sim and Liu, 2001). This two-
step process of DNA degradation during apoptosis is executed
by so-called apoptotic nucleases, primarily by caspase-activated
DNase (CAD) but also Artemis, DNase I, DNase II, DNase
γ, Endonuclease G, topoisomerase II, and cofactors such as
apoptosis-inducing factor (AIF) and cyclophilins (Samejima
and Earnshaw, 2005; Britton et al., 2009; Widlak and Garrard,
2009). Accordingly, MLLbcr cleavage could be part of early
DNA fragmentation into high molecular weight (50–300 kb)
fragments. Deregulated checkpoint control might permit repair
of the resulting DSBs and thus survival, while erroneous DSB
repair might rearrange MLL in some cells mediating malignant
transformation (Stanulla et al., 1997; Hars et al., 2006). Indeed,
genomic mapping revealed that the∼600 bpMLLbcr hotspot for
therapy-related translocations contains not only topoisomerase
II but also topoisomerase I and apoptotic cleavage sites (Mirault
et al., 2006) and was shown to be DNase I-sensitive (Strissel
et al., 1998). In further support of the concept of apoptotic
fragmentation-driven MLL rearrangements, incidence of MLL
fusions was decreased in etoposide-treated mouse embryo
fibroblasts from CAD knockdown mice or after application
of the pan-caspase inhibitor zVAD-fmk (Hars et al., 2006).
Corresponding results were obtained in lymphoblastoid TK6
cells after apoptosis induction with anti-CD95-antibody and
zVAD-fmk exposure (Betti et al., 2003; Le et al., 2009), indicating
that induction ofMLL breakage and rearrangements are observed
downstream of receptor-mediated and mitochondrial pathway-
dependent apoptotic signaling.
However, caspase activation seems not to be required for
MLL breakage and rearrangements in each cellular setting.
Etoposide-induced MLLbcr breakage was caspase-independent
in CEM cells (Mirault et al., 2006). Further, irradiated MCF7
cells, which lack functional caspase-3 and thus CAD activation,
show the same MLLbcr fragmentation as TK6 cells treated
with anti-CD95 antibody (Betti et al., 2005). In our recent
work, we used T47D cells, which are known to mimic the
MLLbcr cleavage pattern of lymphoblastoid cells after genotoxic
treatment (Mirault et al., 2006) and to be particularly responsive
to replication stress induced by aphidicolin. Again, we found
that MLLbcr cleavage is caspase-independent after aphidicolin
treatment despite active apoptosis signaling (Gole et al., 2014).
Moreover, in the context of enhanced replication stress, caspase-
independent Endonuclease G rather than caspase-activated CAD,
topoisomerase I, DNase I, DNase II, or Artemis was essential
for MLLbcr rearrangements in T47D and HeLa cells (Gole
et al., 2014). Replication stress is one of the outcomes of
topoisomerase II-inhibitory treatments, as topoisomerase II
action is required for relaxation of supercoiled DNA during
replication (Felix et al., 1995). Moreover, epipodophyllotoxins
generate reactive oxygen species that create various DNA lesions
ultimately blocking replication (Berquist and Wilson, 2012).
Therefore, erroneous responses to replication stress associated
with replication fork stalling are a possible additional explanation
for MLLbcr breakage and rearrangements after topoisomerase II
inhibition using epipodophyllotoxins.
Properties of the MLLbcr Locus
Collective data showing thatMLLbcr breaks and rearrangements
most likely can be induced by topoisomerase II- or
apoptosis/caspase-mediated but also independent mechanisms
spurred the search for a common denominator, which could
explain breakability of MLLbcr under all these different
conditions. Clues might come from the intrinsic properties
of the MLLbcr region itself. Soon after the discovery of the
involvement of the MLL locus in leukemogenesis it was
proposed that the chromatin structure of the region might play
a role. Thus, the telomeric half of the MLLbcr, which harbors
topoisomerase II-sensitive sites was described to have properties
of a scaffold/matrix-attachment region (SAR/MAR) (Broeker
et al., 1996). Later on, however, it was noticed that the MLLbcr-
DNA breaks showed a higher density outside of high-affinity
SAR/MAR fragments, probably because SAR/MAR-DNA is
protected by a high protein content (Strissel et al., 2000; Hensel
et al., 2001). Similarly, the breakpoint cluster region in the
AFF1/AF4 gene, a common translocation partner of MLL, also
contains MAR features but again with an inverse correlation
between breakage and high-affinity SAR/MAR fragments
(Hensel et al., 2001). On the other hand it was discovered that
the telomeric part of the MLLbcr has characteristics of open
chromatin with high DNase I sensitivity and low histone H1
content (Strissel et al., 1998; Khobta et al., 2004). DNase I
sensitivity peaks in the MLLbcr, similarly as in the promoter of
the MLL gene, is positioned in the 5′-half of exon 12, just 3′ to
the major therapy-related translocation breakpoint (Figure 1C).
The breakpoint cluster region of AFF1/AF4 also showed DNase I
sensitivity (Strick et al., 2006), so that the therapy/infant-related
MLLbcr breaks and rearrangements could be due to increased
accessibility of this translocation hotspot for nucleases such as
topoisomerase II and Endonuclease G. No such features were
described for the centromeric part of the MLLbcr (Figure 1B),
suggesting that the mechanisms of MLL breakage leading to
de novo AL are quite different from the ones in t-AL and
infant ALL.
At first glance contradictory to the proposed impact of the
chromatin context on the fragility of the MLLbcr, experiments
with extrachromosomal episomes containing the therapy-related
MLLbcr fragment or with randomly chromosomally integrated
extraMLLbcr copies showed similar cleavage and rearrangements
of exogenous and the endogenous MLLbcr in situ (Stanulla
et al., 2001; Boehden et al., 2004; Gole et al., 2014). Still, when
investigating a randomly integrated copy of the therapy-related
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 June 2015 | Volume 3 | Article 41
Gole and Wiesmüller MLLbcr destabilizing mechanisms
MLLbcr fragment, we noticed dependency of breakage and
rearrangements on RNF20 (Gole et al., 2014), a histone H2B
monoubiquitinase whose activity has been linked with increased
chromatin accessibility (Fierz et al., 2011). This RNF20 influence
was not found when analyzing extrachromosomal MLLbcr
fragment stability (Gole et al., 2014). Further arguing against
a mere cis-regulatory effect of the MLLbcr DNA sequence,
we saw differences in the inducibility of rearrangements
between cell clones with single copies of the MLLbcr integrated
into different chromosomal sites in K562 myleoid leukemia
cells (Ireno et al., 2014). Taken together, accessibility of
naked or poorly chromatinized DNA within extrachromosomal
episomes or open chromatin at intrachromosomal loci seem
to significantly contribute to the t-AL/infant ALL-related
MLLbcr breaks.
On the other hand, several pieces of evidence argue against
chromatin accessibility as the sole reason for MLLbcr fragility,
as at least two more segments of the MLL gene which are
not recurrently rearranged have DNase I sensitive sites, namely
within the promoter region of exon 1 and within exon 37
(Figure 1A). Interestingly, when murine Mll was introduced
into human cells on an episome, it was cleaved at the site
of the endogenous Mll in murine cells, which was the first
hint that the sequence of MLL itself plays an important role
in breakage distribution (Stanulla et al., 2001). Later on it
was discovered that MLLbcr breaks at non-random positions
at a sequence reminiscent of nick-forming sequences, i.e.,
hypersensitive regions positioned regularly at loop-size intervals
in the eukaryotic chromatin, which are targeted during high-
order apoptotic DNA fragmentation (Székvölgyi et al., 2006).
These sequences may form secondary structures such as hairpins
and these hairpins were proposed to represent the basis of
MLLbcr fragility (Székvölgyi et al., 2006). Indeed, a hairpin
secondary structure was described at a topoisomerase II cleavage
site at the 5′-terminus of MLL exon 12, with positioning of the
topoisomerase II site in the loop and the actual breakpoint at
the stem of the hairpin (Le et al., 2009). A broader look at
the intron 11/exon 12 boundary reveals that the whole region
harboring major therapy-related translocation breakpoints is
predicted to fold into a complex secondary structure with
hairpins (Figure 1D). Such non-B DNA structures can form
during DNA replication when longer runs of single-stranded
DNA are transiently formed as well as in a replication-
independent manner (Wang et al., 2013). When left unresolved,
such structures can obstruct progression of the DNA replication
and/or RNA transcription machinery (Le et al., 2009; Wang et al.,
2013), both of which could contribute to MLLbcr breakage and
further rearrangements (Le et al., 2009) as discussed in more in
detail below.
Replication Stalling or Transcription
Stalling?
Replication Stalling
Breakage of the therapy-related MLLbcr hotspot in response
to treatment with aphidicolin, an inhibitor of polymerase α,
δ, and ε (Ozeri-Galai et al., 2011), indicated involvement
of replication stress in MLLbcr destabilization, particularly as
apoptosis induction was not necessarily coupled with treatment
(Gole et al., 2014). Together with formation of a stable secondary
structure predicted to halt the progression of replication forks
(Figure 1D), these MLLbcr features were reminiscent of so-
called fragile sites (Durkin and Glover, 2007; Ozeri-Galai et al.,
2011; Debatisse et al., 2012). Fragile sites by definition are
loci with frequent breaks under replication stress. While Rare
Fragile Sites (RFS) are found only in few individuals such
as with micro- or mini-satellite repeat expansion-associated
inheritable diseases, Common fragile sites (CFS) are population-
wide hotspots for chromosomal rearrangements, whereby >200
were mapped in humans (Letessier et al., 2011; Debatisse
et al., 2012). CFS were discovered as gaps and constrictions in
metaphase chromosomes of cells grown under mild replication
stress conditions following treatment of cells with aphidicolin
(Glover et al., 1984). Further work showed that CFS are also
responsive to replication impediments such as due to secondary
structures, decelerated replication such as due to depletion of
nucleotide pools, perturbations of replication due to failure of
origin firing or deregulated checkpoint control mechanisms, and
interference with transcription (Letessier et al., 2011; Ozeri-
Galai et al., 2011; Debatisse et al., 2012). Genomic analysis
revealed that CFS are prone to sister chromatid exchange, loss
of heterozygosity, deletions, and tandem segmental genomic
duplications. Intriguingly, CFS correlate with chromosomal
breakpoints in tumors. Altogether, even though not formally
defined as CFS, the therapy-related MLLbcr hotspot shares
crucial characteristics with these fragile sites.
Depending on the cause, severity, and persistence of DNA
replication stress it emerges as stalling and/or collapse of
DNA replication forks. DNA lesions represent an obstacle
to continued fork progression and therefore are a major
source of replication stress. Replication stalling can directly
create DSBs, when the fork encounters a single-stranded
DNA break. However, DSBs may also arise during replication
reactivation, when damage bypass mechanisms transiently
introduce breaks such as during inter-strand DNA cross-link
repair or when strand exchange intermediates are created that
are vulnerable to incisions by structure specific nucleases such
as upon replication fork reversal (Atkinson and McGlynn,
2009; Thompson and Hinz, 2009). Endogenous and exogenous
reactive oxygen species are a prominent source of a wide
spectrum of lesions ranging from base modifications to inter-
strand DNA cross-links (Berquist and Wilson, 2012; Ensminger
et al., 2014). Other replication blocking insults may arise
from environmental, nutritional, and life-style risk factors,
as well as from therapeutic interventions such as chemo-
and radiotherapies, i.e., the well-described cause of secondary
leukemia associated with MLLbcr rearrangements (Shivakumar
et al., 2008; Pullarkat et al., 2009; Shim et al., 2010; Abdulwahab
et al., 2012; Cowell and Austin, 2012). The combination of
deregulated replication and genotoxic stress such as in case
of oncogene- or hormone-induced proliferation together with
reactive oxygen species and reactive metabolite formation,
respectively, seems to be particularly detrimental to the integrity
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of the genome (Bolton and Thatcher, 2008; Macheret and
Halazonetis, 2015).
Replication stress-induced rearrangements could also be the
common trigger for rearrangements within the telomeric MLL
fragment causing both therapy-related and infant ALL (Broeker
et al., 1996; Cimino et al., 1997; Reichel et al., 2001; Cowell
and Austin, 2012; Meyer et al., 2013). HSCs and progenitor
cells, i.e., the cells-of-leukemia-origin, are known to exit from
quiescence into an active cycle upon infection, enforced self-
renewal due to bone marrow transplantation, and in response
to genotoxic insults. A recent publication provided in vivo
evidence in mice for the appearance of DSBs and single-
stranded breaks as a direct consequence of HSC cell cycle
entry under conditions mimicking viral infection (Walter et al.,
2015). Serial transplantation of HSCs into immunodeficient mice
as well as clinical HSC transplantation were shown to trigger
replication stress and persistent DNA damage (Yahata et al.,
2011). The authors identified mitochondrial reactive oxygen
species as mediator of replication stress-induced DNA damage
in both cases. Proliferative stress further correlated with genomic
instability in bone marrow transplants during repopulation of
recipients favoring secondary tumor formation (Hertenstein
et al., 2005; Flynn and Kaufman, 2007). Murine HSCs, when
pushed out of quiescence to reconstitute mature blood cells by
massive self-renewal following irradiation or chemotherapeutic
treatment show hypersensitivity to further genotoxic treatment
and proneness to lymphomagenesis (Cheshier et al., 1999;
Labi et al., 2010; Trumpp et al., 2010; Desai et al., 2014).
MLLbcr rearrangements in t-AL and infant ALL associated
with radio-/chemotherapy and fetal hematopoiesis, respectively,
are thus compatible with HSC exit from quiescence and
hypersensitivity to replication-associated damage. Further clues
to an involvement of replication stress inMLLbcr rearrangements
came from Fanconi anemia (FA) patients, as the FA pathway is
central to the stabilization and reactivation of replication forks
(Thompson and Hinz, 2009). The integrity of the FA pathway
was reported essential to prevent high rates of HSC death upon
replication stress (Ceccaldi et al., 2012; Walter et al., 2015).
Supporting a causal role of replication-associated damage in
MLLbcr rearrangements, therapy-related t(11; 16)-AML with a
MLL-CBP fusion was observed in a pre-B-cell ALL pediatric
patient with FA (Sugita et al., 2000), and MLL partial tandem
duplications (MLL-PTD) were reported in bone marrow samples
from FA patients (Quentin et al., 2011).
Transcription Stalling
As with replication stalling, various hurdles ranging from
repetitive sequences to chromatin changes may also cause
transcription stalling and several pieces of evidence suggested
involvement of transcription stalling in MLLbcr destabilization.
Using chromatin immunoprecipitation (ChIP) in Jurkat
immortalized human T-lymphocytes and human CD34+
HSPCs, the telomericMLLbcr region encompassing the therapy-
related hotspot at intron 11/exon 12 was characterized by
chromatin marks reminiscent of promoters with the lowest
histone H1 content and H4-acetylated islands (Khobta et al.,
2004). In 2007, Marschalek and co-workers (Scharf et al.,
2007) confirmed a chromatin structure that supports active
transcription. Even further, they proposed that this telomeric
MLLbcr fragment colocalizes with a gene-internal promoter
resulting in a truncated MLL protein. Interestingly, the authors
detected a similar putative gene-internal promoter in the
homologous region in the murine Mll. Intriguingly, etoposide-
induced break sites were then mapped at the RNA polymerase
II binding and transcription initiation site within the putative
gene-internal promoter in Jurkat and REH human cell lines as
well as peripheral blood mononuclear cells (Scharf et al., 2007).
However, no such information on a gene-internal promoter at
intron 11/exon 12 is included in current Ensembl data (release
79, March 2015, Cunningham et al., 2015) which assembles
information from 18 different human cell lines (including
K562, DND-41 leukemic T-cells and GM12878 B-lymphocytes).
Nevertheless, a DNase I sensitive open chromatin structure was
detectable in the critical region. It further coincides with binding
sites for CTCF that can function as a transcription factor,
demarcate chromatin domains, and mediate chromosomal
looping interactions (Figures 1B,C). One possibility to reconcile
the different observations could be cell type-dependent
regulatory effects. Importantly, replication and transcription
cannot be looked upon separately, because collisions between
transcription and replication machineries or RNA-DNA hybrid
(R-loops) formed during transcription are known to impede
replication fork progression (Macheret and Halazonetis, 2015).
Conflicts between transcription and replication can stem from
deregulated checkpoint control mechanisms changing the length
of cell cycle phases and the program of origin firing during
malignant transformation processes.
Different views exist also regarding the order of events
leading to DNA breakage and subsequent rearrangements at
transcriptionally active sites. The two major hypotheses imply
either that rearrangements occur after DNA damage at the
juxtaposed sequences/genes (contact first) or due to increased
mobility of distant sequences/genes after DNA damage (breakage
first). The contact first hypothesis implies transcription stalling
as the basis of DNA break formation. In support of such
a model regarding MLL rearrangements, it was noticed that
MLL transcripts can be founded in close proximity to actively
transcribed translocation partners AF4 and AF9 in KG1 myeloid
leukemia cells and Nalm-6 pre-B leukemia cells and AF4 and
AF9 transcripts in close proximity to actively transcribed MLL
(Cowell et al., 2012). This suggests that these genes could be
part of common transcription factories, where simultaneous
DNA breaks on translocation partners in close proximity are
possible. Supporting the common transcription factory/contact
first hypothesis are also observations of MLL-AF4 mRNA
fusion transcripts in the absence of the corresponding gene
fusion in both tumor and normal hematopoietic cells from
infant ALL patients (Uckun et al., 1998) and in peripheral
blood mononuclear cells from healthy individuals (Kowarz
et al., 2011). These observations were interpreted such that
premature termination of transcription may trigger intra- and
to a lesser extent inter-genic trans-splicing events resulting in
fusion transcripts at common transcription factories. Due to
the intriguing coincidence of trans-splicing and translocation
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events involving the same gene pairs, and inspired by findings
from yeast on RNA-templated DNA repair (Storici et al.,
2007), the authors proposed that fusion transcripts may in fact
guide error-prone repair of DNA lesions arising in one of the
translocating genes (Kowarz et al., 2011, 2012). In a recent
study addressing the role of prenatal hormone exposure in MLL
translocations leading to infant ALL, estradiol-inducedMLL and
MLLT3/AF9 colocalization as well as fusion transcript formation
were detected. Interestingly, this process required the protein
activation-induced cytidine deaminase, AID (Wright et al., 2014).
Even though primarily known to be involved in targeted Ig
gene maturation processes, AID has also been shown to exert
unspecific genotoxic effects upon activation by estrogen (Pauklin
et al., 2009). ChIP experiments revealed localization of AID in
MLLbcr intron 11 (Wright et al., 2014), to where it may become
recruited by stalled RNA polymerase in analogy to the situation
during Ig gene switching (Pavri et al., 2010). Given that aberrantly
activated AID can cleave at 150 target sites outside of Ig genes
including well-described translocation hotspots (Hakim et al.,
2012), it represents a key candidate for involvement in genome
rearrangements following transcription stalling.
The breakage first hypothesis positions contact formation
as an event secondary to DNA break formation. One of the
reasons arguing against the contact first hypothesis was that
3D-FISH analysis indicated closer spatial proximity of MLL
and ENL genes in interphase nuclei of myeloid (AML-193,
PLB-985) and lymphoid cells (Nalm-6, IM-9) as compared
with MLL and AF4 genes, even though AF4 represents the
most frequent partner in MLL translocations (Gué et al.,
2006). Evidence supporting breakage as the primary event
leading to chromosome rearrangements was obtained also with
the 3D time-lapse microscopy in living U2OS osteosarcoma
cells using the fluorescently labeled 53BP1-GFP protein as a
DSB marker. These experiments revealed enhanced mobility
of damaged as compared with intact chromatin domains and
susceptibility of only DSB containing chromatin to retardation
of the movements by agents that affect chromatin organization
(Krawczyk et al., 2012). Glukhov and colleagues (Glukhov et al.,
2013) more specifically addressed the mobility of the MLLbcr
in etoposide-treated Jurkat cells. The authors observed that the
telomeric MLLbcr DNA end moved out of the chromosome 11
territory within 1 h following cleavage, which could increase the
probability to meet and erroneously merge with a translocation
partner.
Observations made on the frequency of Igh translocations
in murine B lymphocytes may reconcile the two models in
that they showed that site-directed DNA break formation is
strictly associated with translocations, whereas in the absence
of targeted DNA breaks rearrangements are related to the
contact frequency with the partner genes, i.e., reflect the nuclear
architecture (Hakim et al., 2012). Thus, targeted cleavage seems
to govern downstream events. Notably, MLLbcr cleavage and at
least intramolecular rearrangements do not require higher-order
chromatin structures, take place on non-replicating episomes and
independently of the MLLbcr sequence orientation with respect
to a neighboring transcriptional promoter arguing against an
essential role of replication or transcription stalling immediately
within the MLLbcr (Stanulla et al., 2001; Boehden et al.,
2004; Gole et al., 2014). However, chromosomal structures and
processes promote MLLbcr breakage in cis and/or influence
cleavage in trans such as via early apoptotic signaling and
activation of Endonuclease G (Gole et al., 2014) (Figure 2).
Intriguingly, damaged DNA and complex DNA structures,
such as R-loops, all of which can promote replication and/or
transcription stalling are preferential targets of Endonuclease G-
mediated cleavage (Ruiz-Carrillo and Renaud, 1987; Ohsato et al.,
2002; Kalinowska et al., 2005)making it a strong candidate for the
nuclease responsible forMLLbcr cleavage.
How is Broken MLLbcr Repaired?
The striking disparity in the distribution of breakpoints
associated with de novo vs. therapy-related AL clearly involves
differential targeting of DNA breaks but may additionally
FIGURE 2 | Comprehensive overview of the pathways leading to
MLLbcr rearrangements. Exposure of the cells to genotoxic agents can
directly or indirectly cause stalling of DNA replication, e.g., by antimetabolite
treatment, and by formation of DNA adducts and downstream repair
intermediates (e.g., by treatment with alkylating agents and downstream
excision repair) or transcription stalling, respectively. Excessive proliferation of
the hematopoietic stem/progenitor cells (cells-of-leukemia-origin) due to
enforced self-renewal after bone marrow transplantation or genotoxic insults
also results in replication stress. MLLbcr in turn is cleaved either as part of the
attempt to rescue stalled forks or as part of DNA damage-induced early
apoptotic high order DNA fragmentation. DSBs at the MLLbcr can be repaired
through NHEJ, MMEJ, or homology-directed repair which can lead to
leukemogenic rearrangements preventing further oligomeric DNA
fragmentation and cell death.
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be influenced by the involvement of specific DNA repair
mechanisms (Broeker et al., 1996). So far, most of the information
on the involvement of DNA repair pathways originated from
the mapping of fusion points and the analysis of rearranged
sequences. In this way, Alu repeat-mediated homology-directed
repair was shown to create partial tandemMLL duplications in a
group of de novoAML patients (So et al., 1997; Strout et al., 1998).
The corresponding Alu elements are present in MLL intron 1
and in the centromeric part of the MLLbcr, and consequently
are not involved in therapy-associated rearrangements mostly
affecting the telomeric part of the MLLbcr. On the other
hand, collective data from several groups were interpreted
such that non-homologous end-joining (NHEJ) is the major
mechanism for the creation of translocations. Sequence analysis
of intergenic fusions frequently lacked overlapping homologies
or revealed micro-homologies (mini-direct repeats) rather than
extended homologies, which pointed to misrepair by error-prone
classical NHEJ or alternative microhomology-mediated end
joining (MMEJ) mechanisms (Reichel et al., 2001; Whitmarsh
et al., 2003; Le et al., 2009). These features were detected
in infant and adult ALL as well as t-AL patients and
consequently in centromeric and telomeric MLLbcr regions.
More specifically,MLL-AF4 fusions in 40 ALL patients diagnosed
with t(4;11) showed filler DNA of≤21 nucleotides andmini-direct
repeats of ≤7 nucleotides at the inter-chromosomal junctions
in more than half of the cases. Additionally, duplications
of ≤463 nucleotides of parental sequences, inversions of ≤267
nucleotides, and/or deletions of ≤4413 nucleotides were found
(Reichel et al., 2001). Analysis of a t-AML case diagnosed
with t(9;11) revealed a MLL-AF9 translocation fusing a micro-
homologous TATTA sequence without gain or loss of any
further nucleotides (Whitmarsh et al., 2003). Analysis of blood
samples from breast cancer and lymphoma patients undergoing
chemotherapeutic treatments identified MLL rearrangements
with micro-homologous sequences of 2–8 bp in most of the
junction sequences (Le et al., 2009). Even ex vivo flavonoid
exposure of primary human CD34+ HSPCs was demonstrated
to induce DSBs and translocations in theMLL intron 11/exon 12
regionmostly via error-prone repair involvingmicro-homologies
but in fewer cases via homology-directed repair at Alu-like
sequences (van Waalwijk van Doorn-Khosrovani et al., 2007).
Interestingly, in almost all presumed MMEJ cases repetitive
LINE/L1 or SINE/Alu-like elements were detected adjacent to the
breakpoints on at least one side and short palindromic sequences
predicted to be formed. When Zinc Finger Nuclease technology
was used to introduce cuts precisely within theMLL, detrimental
genetic changes were only observed upon additional inhibition
of the key NHEJ factor DNA-PK, which was accompanied
by a rise in homology-directed activities (Do et al., 2012).
This result suggested that clean breaks within the MLLbcr less
frequently cause leukemogenic rearrangements, because they are
quickly removed by classical NHEJ. Biochemical analysis indeed
demonstrated association of DNA-PK with theMLLbcr following
ionizing irradiation-induced breakage (Betti et al., 2001).
With the advance of technologies—starting from the
analysis of cytogenetically defined karyotypes toward long-
distance inverse PCR-based sequence analysis—detection of
genomic changes has seen a dramatic sensitivity rise. Reflecting
higher resolution, the spectrum of newly described MLLbcr
rearrangements became larger in recent years. Previously,
MLL was known to predominantly participate in reciprocal
chromosomal translocations. More recently, non-reciprocal
rearrangements resulting in insertions, inversions, and deletions
were identified to account for a significant fraction of MLLbcr
rearrangements. Complex rearrangements requiring at least tree
DSBs and involving at least two chromosomes were observed
to account for a fraction of up to 26% of MLL rearrangements.
Complex rearrangements may result in three-way translocations,
chromosomal translocations associated with deletions or with
fragment insertions. In the most extreme case of complex
chromosomal translocations many fusion alleles are generated
during a single cell division in a process called chromothripsis
(De Braekeleer et al., 2011; Cerveira et al., 2012; Meyer et al.,
2013).
A major source of non-reciprocal complex rearrangements
is break-induced replication, whereby replication fork collapse
can be induced by ionizing irradiation or oncogenes followed
by processing into one-ended DSBs, which are repaired
by break-induced replication, a form of homology-directed
repair, which involves replication template switching (Macheret
and Halazonetis, 2015). Desai et al. (2014) demonstrated
reliance of HSPCs, the cells-of-leukemia-origin, on homology-
directed repair for DSB processing upon exit from quiescence.
Thus, pushing HSPCs of homology-directed repair-deficient
Exo1 mutant mice into the cell cycle by treatment with 5-
Fluorouracil or poly-IC caused hypersensitivity to ionizing
radiation. There is also evidence for MLLbcr rearrangements
by the homology-directed repair mechanism homologous
recombination, i.e., the DSB repair pathway considered to
be most error-free. First, sequence analysis of partial tandem
duplications of the MLL gene in AML patients suggested
recombination between imperfectly homologous Alu sequences
through generation of a heteroduplex fusion (Strout et al.,
1998). Second, knockdown experiments of replication stress-
induced MLLbcr rearrangements indicated involvement of
RAD51 (Gole et al., 2014). Third, a pathogenic role of altered
ATM function was proposed, when a germline missense ATM
mutation was detected in the phosphatidylinositol-3 (PI-3)
kinase coding region of a pediatric leukemia patient with
MLL rearrangement (Oguchi et al., 2003). ATM deficiency
was further shown to result in excessive binding of the DNA
recombination protein RAD51 at the MLLbcr translocation
breakpoint hotspot of 11q23 chromosome translocation after
etoposide exposure. Binding of Replication protein A (RPA)
and the chromatin remodeler INO80, which facilitate RAD51
loading on damaged DNA, to the hotspot were also increased
by ATM deficiency. Thus, in addition to activating DNA
damage signaling, ATM may avert chromosome translocations
by preventing excessive loading of recombinational repair
proteins onto translocation breakpoint hotspots (Sun et al.,
2010). In this context it is of interest that reduced ATM
levels were found in cycling human HSPCs as compared with
cycling mature human peripheral blood lymphocytes (Kraft
et al., 2015), providing one possible explanation for HSPC
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proneness to aberrant homologous recombination events at the
MLLbcr.
Conclusions
Therapy-induced leukemia represents the most severe side effect
of chemotherapy after successful treatment of the primary
tumor. Evaluation of population-based data for the years
1975–2008 from nine US cancer registries revealed a t-AML
incidence of 5.7% among the 29% of cancer patients who had
received initial chemotherapy (Morton et al., 2013). During the
observation period the t-AML risk rose among some cancer
patients like non-Hodgkin lymphoma (NHL) patients, while it
declined among others like ovarian carcinoma patients. Changes
were explained by more frequent administration of subsequent
therapies for persistent or relapsed NHL and a shift from
an alkylating (melphalan) to a crosslinking (platinum) drug-
based chemotherapy of ovarian carcinoma, documenting the
influence of cumulative dose and the mode-of-action of the drug.
Accordingly, attempts to optimize treatment modalities have
focused on dose- and drug-adaptation in analogy to reduced-
intensity conditioning regimens for patients requiring bone
marrow transplantation (Myers and Davies, 2009). However, a
recent study showed that the risk of secondary malignancies
did not decline with reduced-intensity and reduced-toxicity
conditioning regimens (Shimoni et al., 2013). Moreover, the
benefits from modern medicine with a 3% annual increase
of successfully treated cancer survivors, call our attention to
the predicted rise in secondary malignancy risk (Maddams
et al., 2011; Dong and Chen, 2014). Knowing that age is
the most prominent cancer risk factor, the worldwide rise in
longevity will further increase cancer incidences. Additionally,
the hematopoietic system accumulates replication stress damage
with age (Flach et al., 2014), which may rise the vulnerability
for chemotherapy-induced MLLbcr rearrangements (Gole et al.,
2014). So far, the benefits of chemotherapy significantly outweigh
the risk of adverse effects (Dong and Chen, 2014). Novel
targeted approaches such as PARP or mTOR inhibitor therapies
inducing replication stress and EndoG nuclear translocation,
respectively, may also bear a risk of MLLbcr destabilization
(Gole et al., 2014). Hopes for better survival of patients
with MLL-rearranged leukemia come from novel treatment
regimens such as a triple immunotherapy targeting tumor-
associated antigen and natural killer cell resistance (Chan
et al., 2012). The challenge for the future will, however, be to
identify markers for secondary leukemia risk and to develop
compounds preventing t-AML for rational design of personalized
combination therapies.
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